



Merseyside Inter Agency Drug Misuse Database

Warrington DAT

Quarter 4 2007/08

**Lloyd Baron, Martin Chandler,
Jim McVeigh**

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531

m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521

L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Syringe Exchange Services	5
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 13: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
Pharmacy	10
Table 14: Individuals by Gender	
Table 15: Individuals by Age Group	
Table 16: Year to Date, by Gender & Age Group	
Combined	11
Table 17: Individuals in Syringe Exchange, by Gender	
Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 19: Individuals in Syringe Exchange, by Age Group	
Table 20: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 21: Year to Date, by Gender & Age Group	
Table 22: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 13

Table 23: Individuals in contact with Treatment Services, by Gender

Table 24: Year to Date, by Gender

Table 25: Individuals in contact with Treatment Services, by Age Group

Table 26: Year to Date, by Age Group

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Table 28: Individuals in contact with Treatment Services, by Main Drug of Use

Combined Datasets 16

Table 29: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 30: Year to Date, by Gender & Age Group

Cross Matched Datasets 17

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

PLEASE NOTE: The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report. However, Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in

order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)**Quarter 4 (2007/08)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	29	82.9
Female	6	17.1
Age Group		
Under 18	0	0.0
18-19	1	2.9
20-24	6	17.1
25-29	13	37.1
30-34	5	14.3
35-39	7	20.0
40-44	3	8.6
45+	0	0.0
Total	35	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0.0	0	0.0	0	0.0
18-19	3	4.0	0	0.0	3	3.3
20-24	12	16.0	2	12.5	14	15.4
25-29	17	22.7	6	37.5	23	25.3
30-34	10	13.3	7	43.8	17	18.7
35-39	21	28.0	0	0.0	21	23.1
40-44	9	12.0	1	6.3	10	11.0
45+	3	4.0	0	0.0	3	3.3
Total	75	100	16	100	91	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	1	1
Benzodiazepines	8	1
Cannabis	3	3
Crack	11	3
Cocaine	3	5
Ecstasy	0	0
Heroin	12	3
Methadone	0	2
Other	5	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES

Quarter 4 (2007/08)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	23	95.8
Female	1	4.2
<i>Total</i>	<i>24</i>	<i>100</i>
All Clients		
Male	68	94.4
Female	4	5.6
<i>Total</i>	<i>72</i>	<i>100</i>

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	13	100
Female	0	0.0
<i>Total</i>	<i>13</i>	<i>100</i>
All Clients		
Male	31	91.2
Female	3	8.8
<i>Total</i>	<i>34</i>	<i>100</i>

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	8.3	4	5.6
20-24	7	29.2	13	18.1
25-29	5	20.8	10	13.9
30-34	3	12.5	18	25.0
35-39	6	25.0	20	27.8
40-44	1	4.2	7	9.7
45+	0	0.0	0	0.0
Total	24	100	72	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	2	15.4	2	5.9
25-29	2	15.4	2	5.9
30-34	3	23.1	9	26.5
35-39	5	38.5	14	41.2
40-44	1	7.7	7	20.6
45+	0	0.0	0	0.0
Total	13	100	34	100

Table 8: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	4	5.9	0	0.0
20-24	12	17.6	1	25.0
25-29	10	14.7	0	0.0
30-34	17	25.0	1	25.0
35-39	19	27.9	1	25.0
40-44	6	8.8	1	25.0
45+	0	0.0	0	0.0
Total	68	100	4	100

Table 9: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	2	6.5	0	0.0
25-29	2	6.5	0	0.0
30-34	8	25.8	1	33.3
35-39	13	41.9	1	33.3
40-44	6	19.4	1	33.3
45+	0	0.0	0	0.0
Total	31	100	3	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	9	2.4	0	0.0	9	2.2
20-24	64	16.9	6	25.0	70	17.4
25-29	86	22.8	1	4.2	87	21.6
30-34	87	23.0	5	20.8	92	22.9
35-39	82	21.7	6	25.0	88	21.9
40-44	35	9.3	3	12.5	38	9.5
45+	15	4.0	3	12.5	18	4.5
Total	378	100	24	100	402	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	<1	0	0.0	1	<1
20-24	9	6.8	5	21.7	14	9.0
25-29	16	12.1	1	4.3	17	11.0
30-34	39	29.5	5	21.7	44	28.4
35-39	45	34.1	6	26.1	51	32.9
40-44	17	12.9	3	13.0	20	12.9
45+	5	3.8	3	13.0	8	5.2
Total	132	100	23	100	155	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	10	43.5	0	0.0
Methadone	0	0.0	0	0.0
Steroids	10	43.5	1	100
Other	3	13.0	0	0.0
Total	23	100	1	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request. The client figures recorded for Drug of Use are based on the limited drug information provided and are not representative of the number of new clients overall.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta- mine		Benzodi- azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18-19	-	-	-	-	-	-	-	-	-	-	-	-	2	18.0
20-24	-	-	-	-	-	-	-	-	2	20.0	-	-	5	45.0
25-29	-	-	-	-	-	-	-	-	2	20.0	-	-	3	27.0
30-34	-	-	-	-	-	-	-	-	2	20.0	-	-	-	-
35-39	-	-	-	-	-	-	-	-	3	30.0	-	-	1	9.0
40-44	-	-	-	-	-	-	-	-	1	10.0	-	-	-	-
45+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total*	-	-	-	-	-	-	-	-	10	100	-	-	11	100

* % Totals are by Drug, not Age Group

PHARMACY SYRINGE EXCHANGE

Table 14: Individuals by Gender

New Clients	n	%
Male	56	84.8
Female	10	15.2
<i>Total</i>	66	100
All Clients		
Male	159	87.4
Female	23	12.6
<i>Total</i>	182	100

Table 15: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	3.0	3	1.6
18-19	4	6.1	8	4.4
20-24	18	27.3	47	25.8
25-29	9	13.6	31	17.0
30-34	16	24.2	33	18.1
35-39	11	16.7	36	19.8
40-44	5	7.6	12	6.6
45+	1	1.5	12	6.6
<i>Total</i>	66	100	182	100

Table 16: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	>1	0	0.0	3	>1
18-19	19	6.0	0	0.0	19	5.4
20-24	94	29.7	2	5.4	96	27.1
25-29	53	16.7	7	18.9	60	16.9
30-34	62	19.6	12	32.4	74	20.9
35-39	52	16.4	7	18.9	59	16.7
40-44	23	7.3	4	10.8	27	7.6
45+	11	3.5	5	13.5	16	4.5
<i>Total</i>	317	100	37	100	354	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	76	88.4
Female	10	11.6
<i>Total</i>	86	100
All Clients		
Male	217	89.7
Female	25	10.3
<i>Total</i>	242	100

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	66	88.0
Female	9	12.0
<i>Total</i>	75	100
All Clients		
Male	180	88.2
Female	24	11.8
<i>Total</i>	204	100

*Only known steroid users, based on Agency SES data, have been omitted.

Table 19: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	2.3	3	1.2
18-19	6	7.0	12	5.0
20-24	24	27.9	57	23.6
25-29	14	16.3	39	16.1
30-34	17	19.8	49	20.2
35-39	17	19.8	53	21.9
40-44	5	5.8	17	7.0
45+	1	1.2	12	5.0
<i>Total</i>	86	100	242	100

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	2.7	3	1.5
18-19	4	5.3	8	3.9
20-24	19	25.3	46	22.5
25-29	11	14.7	31	15.2
30-34	17	22.7	40	19.6
35-39	16	21.3	47	23.0
40-44	5	6.7	17	8.3
45+	1	1.3	12	5.9
Total	75	100	204	100

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	>1	0	0.0	3	>1
18-19	27	4.1	0	0.0	27	3.8
20-24	151	23.1	8	14.5	159	22.5
25-29	132	20.2	7	12.7	139	19.6
30-34	140	21.4	14	25.5	154	21.8
35-39	123	18.8	11	20.0	134	18.9
40-44	51	7.8	7	12.7	58	8.2
45+	26	4.0	8	14.5	34	4.8
Total	653	100	55	100	708	100

Table 22: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	1,785	5,509	7,294	21,760

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2007/08)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	103	76.9
Female	31	23.1
<i>Total</i>	<i>134</i>	<i>100</i>
All Clients		
Male	675	75.1
Female	224	24.9
<i>Total</i>	<i>899</i>	<i>100</i>

Table 24: Year to Date, by Gender

New Clients	n	%
Male	246	75.2
Female	81	24.8
<i>Total</i>	<i>327</i>	<i>100</i>
All Clients		
Male	758	75.7
Female	243	24.3
<i>Total</i>	<i>1001</i>	<i>100</i>

Table 25: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	11	8.2	46	5.1
18-19	7	5.2	38	4.2
20-24	16	11.9	82	9.1
25-29	29	21.6	132	14.7
30-34	26	19.4	188	21.0
35-39	28	20.9	222	24.6
40-44	10	7.5	121	13.4
45+	7	5.2	70	7.8
Total	134	100	899	100

Table 26: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	29	8.9	84	8.4
18-19	18	5.5	39	3.9
20-24	38	11.6	104	10.4
25-29	72	22.0	209	20.9
30-34	69	21.1	239	23.9
35-39	62	19.0	192	19.2
40-44	29	8.9	83	8.3
45+	10	3.1	51	5.1
Total	327	100	1001	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	130	97.0	879	97.8
White Irish	1	>1	5	>1
Other White	1	>1	1	>1
White & Black Caribbean	0	0.0	1	>1
White & Asian	0	0.0	1	>1
Other Mixed	1	>1	2	>1
Other Asian	1	>1	2	>1
African	0	0.0	1	>1
Other Black	0	0.0	1	>1
Other	0	0.0	5	>1
Unknown	0	0.0	1	>1
Total	134	100	899	100

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	70	52.2	522	58.1
Methadone	1	>1	60	6.7
Other Opiates	2	1.5	25	2.8
Benzodiazepine	2	1.5	9	1.0
Amphetamines	5	3.7	20	2.2
Cocaine	25	18.7	102	11.3
Crack	5	3.7	20	2.2
Ecstasy	1	>1	7	>1
Cannabis	21	15.7	124	13.8
Other/Unknown	2	1.4	10	1.2
Total	134	100	899	100

COMBINED DATASETS

Quarter 4 (2007/08)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 29: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	846	78.3
Female	234	21.7
Age Group		
Under 18	71	6.6
18-19	48	4.4
20-24	146	13.5
25-29	213	19.7
30-34	247	22.9
35-39	209	19.4
40-44	91	8.4
45+	55	5.1
Total	1080	100

Table 30: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	38	2.7	23	8.1	61	3.6
18-19	72	5.1	15	5.3	87	5.1
20-24	248	17.6	27	9.5	275	16.2
25-29	241	17.1	47	16.5	288	17.0
30-34	287	20.3	60	21.1	347	20.4
35-39	297	21.0	53	18.6	350	20.6
40-44	141	10.0	39	13.7	180	10.6
45+	88	6.2	21	7.4	109	6.4
Total	1412	100	285	100	1697	100

CROSS-MATCHED DATASETS

Quarter 4 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets




Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

